Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation

Leuk Res. 2010 Apr;34(4):e91-3. doi: 10.1016/j.leukres.2009.09.009. Epub 2009 Oct 6.

Authors

Edgar Faber, Renata Mojzikova, Radek Plachy, Sarka Rozmanova, Marek Stastny, Martina Divoka, Marie Jarosova, Karel Indrak, Vladimir Divoky

PMID: 19811824
DOI: 10.1016/j.leukres.2009.09.009

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Amino Acid Substitution / physiology
Antineoplastic Agents / therapeutic use
Cytogenetic Analysis
Dasatinib
Drug Resistance, Neoplasm / genetics*
Humans
Leucine / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Male
Middle Aged
Phenylalanine / genetics
Protein Structure, Tertiary / genetics
Proto-Oncogene Proteins c-bcr / chemistry
Proto-Oncogene Proteins c-bcr / genetics*
Pyrimidines / therapeutic use*
Thiazoles / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Pyrimidines
Thiazoles
Phenylalanine
Proto-Oncogene Proteins c-bcr
Leucine
Dasatinib